Triple-negative breast cancer Press Release
|06/09/2020 - 09:07||
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO and KEYTRUDA Plus Chemotherapy
|05/18/2020 - 19:54||
Genome Study Links DNA Changes to the Risks of Specific Breast Cancer Subtypes
Findings may eventually improve ability to predict breast cancer risks, even at specific breast cancer subtype level.
|05/11/2020 - 12:56||
TRODELVY (sacituzumab govitecan-hziy), FDA Approved for Treatment of Metastatic Triple-negative Breast Cancer, Available Only at Biologics by McKesson
CARY, N.C., May 11, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Immunomedics, Inc.
|05/01/2020 - 12:53||
Researchers Identify Molecular Markers That May Help Predict Disease Recurrence Risk For Triple-Negative Breast Cancer Patients
Research led by scientists at the Johns Hopkins Kimmel Cancer Center report they have identified a set of molecular markers linked to a chemical process called methylation that may help predict the risk of cancer recurrence within five years for patients with triple-negative breast cancer.
|Johns Hopkins H...|
|04/22/2020 - 17:46||
FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments
Today, the U.S. Food and Drug Administration granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer that has spread to other parts of the body. Patients must have received at least two prior therapies before taking Trodelvy.
|04/03/2020 - 02:10||
Indigenous American Ancestry May Be Associated with HER2-positive Breast Cancer
PHILADELPHIA – An increased proportion of Indigenous American (IA) ancestry was associated with a greater incidence of HER2-positive breast cancer, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.
|03/12/2020 - 22:27||
SELLAS Life Sciences Reports Full Year 2019 Financial Results and Provides Business Update
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today reported financial results for the year ended December 31, 2019 and provided a business update.
|SELLAS Life Sciences|
|02/13/2020 - 21:51||
SELLAS Life Sciences Provides Regulatory Update for Nelipepimut-S (NPS) for Triple Negative Breast Cancer (TNBC) Following FDA Feedback
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced feedback from a Type C review with the U.
|SELLAS Life Sciences|
|12/13/2019 - 07:57||
SUSAN G. KOMEN COMMENDS RESULTS OF CLINICAL TRIAL ON CIRCULATING TUMOR DNA IN TRIPLE NEGATIVE BREAST CANCER PATIENTS
Bryan Schneider, that moves us closer to predicting recurrence and informing the treatment of triple negative breast cancer (TNBC). The results were presented at the 2019 San Antonio Breast Cancer Symposium.
|Susan G Komen|
|12/13/2019 - 07:57||
Circulating Tumor DNA May Help Predict Recurrence in Patients with Early Triple-Negative Breast Cancer
SAN ANTONIO — The presence of circulating tumor DNA (ctDNA) in early-stage triple-negative breast cancer helped predict the risk of recurrence in women who had undergone surgery after neoadjuvant chemotherapy, according to data presented at the 2019 San Antonio Breast Cancer Symposium (SABCS), held Dec.
|12/13/2019 - 03:29||
SUSAN G. KOMEN STUDY CONFIRMS TREATMENT OPTIONS FOR HER2-NEGATIVE PATIENTS WITH BRCA1/2 MUTATIONS
San Antonio, Texas — December 13, 2019 — Susan G. Komen®, the world’s leading breast cancer organization, today welcomed the results of the INFORM trial that were announced at the 2019 San Antonio Breast Cancer Symposium. The Komen-funded INFORM trial led by Dr. Nadine Tung shows that HER2-negative patients with a BRCA1/2 gene mutation have multiple effective treatment options.
|Susan G Komen|
|12/12/2019 - 11:22||
Black/White Breast Cancer Subtype Incidence in Men Differs from Trends in Women
Reasons for the elevated risk of breast cancer in black men are largely unknown but may involve multitude of risk factors including genetic and non-genetic factors Incidence rates for hormone receptor positive (HR+) breast cancers are considerably higher in black men than white men, in stark contrast to lower incidence rates of those cancer subtypes in black versus white women.
|12/12/2019 - 10:25||
Neoadjuvant Treatment with Pembrolizumab Improves Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer with Lymph Node Involvement
The addition of the anti-PD-1 immunotherapeutic pembrolizumab (Keytruda) to neoadjuvant chemotherapy increased the rates of pathologic complete response (pCR) in patients with triple-negative breast cancer (TNBC) who had lymph node involvement, according to results from the KEYNOTE-522 trial, which were presented at the San Antonio Breast Cancer Symposium, held Dec.
|12/12/2019 - 08:55||
Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer
The addition of the anti-PD-L1 immunotherapeutic atezolizumab (Tecentriq) to neoadjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) did not improve the rate of pathologic complete response when compared to chemotherapy alone, according to preliminary results from the NeoTRIPaPDL1 trial, which were presented at the San Antonio Breast Cancer Symposium, held Dec.
|12/11/2019 - 18:05||
Biothera Pharmaceuticals Presents Updated Phase 2 Data for Chemo-refractory Triple Negative Breast Cancer Patients at San Antonio Breast Cancer Symposium
The study is evaluating Biothera’s Imprime PGG, a systemically delivered dectin receptor agonist that triggers anti-cancer immune responses, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). Study participants had not been previously treated with immune checkpoint inhibitors and were identified as biomarker positive for Imprime PGG therapy.
|12/09/2019 - 06:41||
Researchers identify gene behind spread of deadly breast cancer
Researchers have uncovered novel targets for breast cancer therapies. Above, a 3D composite of fluorescent pictures shows invasive human triple breast cancer cells (green), compared to cells (red) with reduced levels of the splicing factor TRA2β, which limits the cell’s invasive potential.
|12/05/2019 - 12:54||
OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO and KEYTRUDA in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced it will present interim efficacy, immunological and safety data from its ongoing KEYNOTE-890 study of TAVO™ in combination with KEYTRUDA® in patients with late-stage, heavily pretreated, chemo-refractory metastatic triple negative breast cancer (mTNBC) at the upcoming San Antonio Breast Cancer Symposium (SABCS) Annual Meeting being held December 10-14, 2019.
|12/05/2019 - 09:11||
EISAI TO PRESENT NEW RESEARCH ON ERIBULIN (HALAVEN) AT 42ND ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the latest information on its in-house discovered and developed eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN®, “eribulin”) will be presented during the 42nd San Antonio Breast Cancer Symposium (SABCS2019). The symposium will be held from December 10 through 14, 2019, in San Antonio, Texas in the United States.
|12/04/2019 - 05:44||
Biothera Pharmaceuticals Phase 2 Triple Negative Breast Cancer Data Selected for Spotlight Session at San Antonio Breast Cancer Symposium
Response and clinical benefit assessment of the combination of the dectin-1 agonist imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)
|12/03/2019 - 19:01||
Peterson Receives Grant for Innovative Approach to Attacking Metastatic Triple-Negative Breast Cancer
Jeffrey Peterson, PhD, associate professor of cancer biology with the Breast Cancer Translational Research Disease Group at Fox Chase, will expand upon his previous studies showing that TNBC cells have an increased reliance upon the antioxidant glutathione to avoid cell death through ferroptosis, a form of programmed cell death.
|11/20/2019 - 18:16||
CSUN Prof Identifies New Approach for Targeting Breast Cancer Metastasis
Media Contact: Carmen Ramos Chandler (818) 677-2130 Comments Off on CSUN Prof Identifies New Approach for Targeting Breast Cancer Metastasis.
|11/15/2019 - 09:09||
Impact of Treatment Delays on Survival Did Not Vary by Breast Cancer Type
But while preoperative chemotherapy is sometimes advocated solely to rush the start of treatment faster than surgery, unless delays are anticipated, these data tell us that switching the order of treatment specifically for this reason is not likely to help these patients. Most importantly, there need not be panic about starting treatment more quickly about triple-negative tumors as versus others.”
|Fox Chase Cance...|
|10/30/2019 - 11:14||
Award Winners Named for the 2019 San Antonio Breast Cancer Symposium
SAN ANTONIO — The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, will honor two renowned researchers for their work in breast cancer at the 2019 SABCS, to be held Dec.
|10/29/2019 - 13:51||
Id found my people: Triple negative breast cancer patient builds community at UTSW
DALLAS – Oct. 29, 2019 – Sandra McKinney grew so attached to the Simmons Cancer Center at UT Southwestern that she decided to fly back for follow-up appointments instead of finding a new provider when she moved to New Jersey.
|10/22/2019 - 16:27||
8 BCRF research grants supported by employee and customer donations
Research is the driving force behind Delta’s efforts to raise funds and generate awareness for the Breast Cancer Research Foundation. Because of this research, there has been a 40 percent decline in breast cancer deaths and there are currently 3.5 million survivors in the U.S. today. But there’s still more to do, which is why Delta is proud to partner with BCRF, the highest-rated breast cancer organization in the country, to help put an end to this disease.